XML 64 R26.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Subsequent Events Subsequent Events | 3 Months Ended
--- | ---
Mar. 31, 2018
Subsequent Events [Abstract] |
Subsequent Events | Pfizer Inc. In April 2018 we completed an agreement to acquire from Pfizer BIIB104 (formerly known as PF-04958242), a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia (CIAS). AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. In connection with the closing of this transaction in the second quarter of 2018, we made an upfront payment of $75.0 million. We may also pay Pfizer up to $515.0 million in additional development and commercialization milestone payments, including $10.0 million upon the dosing of the first patient in Phase 2b, as well as tiered royalties in the low to mid-teen percentages. Ionis Pharmaceuticals, Inc. In April 2018 we entered into a new ten-year exclusive collaboration agreement with Ionis Pharmaceuticals, Inc. (Ionis) to develop novel antisense oligonucleotide drug candidates for a broad range of neurological diseases. Under this agreement, we will make an upfront payment of $375.0 million and purchase $500.0 million of Ionis’ common stock, at a 25% premium based on the closing price of Ionis’s common stock for the 10 days prior to the date of this agreement, for a total payment of $1.0 billion. The premium paid on the equity will be recorded as research and development expense in our condensed consolidated statements of income. We have the option to license therapies arising out of this collaboration and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to $125.0 million or $270.0 million, depending on the indication, and royalties on net sales. The transaction is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and is expected to close in the second quarter of 2018.

X
- References No definition available. + Details
Name: | us-gaap_SubsequentEventsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 855 -URI http://asc.fasb.org/topic&trid=2122774 + Details
Name: | us-gaap_SubsequentEventsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration